XR9051 | CAS#762219-35-2 | P-gp Inhibitor | P-gp

MedKoo Cat#: 405550 | Name: XR9051

Description:

WARNING: This product is for research use only, not for human or veterinary use.

XR9051 is as a potent modulator of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) following a synthetic chemistry programme based on a natural product lead compound. XR9051 was shown to be a potent inhibitor of the binding of the cytotoxic to P-glycoprotein (EC50 = 1.4 +/- 0.5 nM). XR9051 reverses the MDR phenotype through direct interaction with P-glycoprotein.

Chemical Structure

XR9051

CAS#762219-35-2 (free)

Theoretical Analysis

MedKoo Cat#: 405550

Name: XR9051

CAS#: 762219-35-2 (free)

Chemical Formula: C39H40N4O5

Exact Mass: 644.2999

Molecular Weight: 644.76

Elemental Analysis: C, 72.65; H, 6.25; N, 8.69; O, 12.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

762219-35-2 (free) 180422-22-4 (HCl)

Synonym

XR9051; XR-9051; XR 9051.

IUPAC/Chemical Name

3-((Z)-((Z)-5-benzylidene-4-methyl-3,6-dioxopiperazin-2-ylidene)methyl)-N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)benzamide

InChi Key

RTIZZWMBGKGLFO-YWQXDYITSA-N

InChi Code

InChI=1S/C39H38N4O5/c1-42-34(22-27-8-5-4-6-9-27)38(45)41-33(39(42)46)21-28-10-7-11-30(20-28)37(44)40-32-14-12-26(13-15-32)16-18-43-19-17-29-23-35(47-2)36(48-3)24-31(29)25-43/h4-15,20-24H,16-19,25H2,1-3H3,(H,40,44)(H,41,45)/b33-21-,34-22-

SMILES Code

O=C(NC1=CC=C(CCN2CC3=C(C=C(OC)C(OC)=C3)CC2)C=C1)C4=CC=CC(/C=C(C(N(C)/C5=C\C6=CC=CC=C6)=O)\NC5=O)=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 644.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1. Methods and means for the treatment of cancer using a combination of a BCRP inhibitor and/or a P-gp inhibitor with an imidazotetrazine chemotherapeutic agent By Van Tellingen, Olaf From U.S. Pat. Appl. Publ. (2009), US 20090170880 A1 20090702. 2. Quinazolin-4-ylaminopyrazolecarboxamides as aurora kinase inhibitors useful in bombination therapy for the treatment of cancer and their preparation By Keen, Nicholas John From PCT Int. Appl. (2007), WO 2007132215 A1 20071122. 3. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators By Globisch, Christoph; Pajeva, Ilza K.; Wiese, Michael From Bioorganic & Medicinal Chemistry (2006), 14(5), 1588-1598. 4. Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer By Prehm, Peter From PCT Int. Appl. (2005), WO 2005013947 A2 20050217. 5. P glycoprotein in human immunodeficiency virus type 1 infection and therapy By Sankatsing, Sanjay U. C.; Beijnen, Jos H.; Schinkel, Alfred H.; Lange, Joep M. A.; Prins, Jan M. From Antimicrobial Agents and Chemotherapy (2004), 48(4), 1073-1081. 6. Improving bioavailability of orally administered drugs, screening for enhancers of such bioavailability and oral drug delivery compositions By Schellens, Johannes Henricus Matthias; Schinkel, Alfred Hermanus From U.S. Pat. Appl. Publ. (2002), US 20020128282 A1 20020912. 7. Method and composition for modulating amyloidosis By Reiner, Peter B.; Lam, Fred Chiu-Lai From U.S. Pat. Appl. Publ. (2002), US 20020037843 A1 20020328. 8. Use of membrane vesicles to investigate drug interactions with transporter proteins, P-glycoprotein and multidrug resistance-associated protein By Wheeler, R.; Neo, S.-Y.; Chew, J.; Hladky, S. B.; Barrand, M. A. From International Journal of Clinical Pharmacology and Therapeutics (2000), 38(3), 122-129. 9. A method of improving bioavailability of orally administered drugs, screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs By Schellens, Johannes Henricus Matthias; Schinkel, Alfred Hermanus From PCT Int. Appl. (2000), WO 2000069390 A2 20001123. 10. Communication between multiple drug binding sites on P-glycoprotein By Martin, Catherine; Berridge, Georgina; Higgins, Christopher F.; Mistry, Prakash; Charlton, Peter; Callaghan, Richard From Molecular Pharmacology (2000), 58(3), 624-632